Are Options Indicating a Surge in Masimo Stock?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 03 2025
0mins
Should l Buy MASI?
Source: NASDAQ.COM
Masimo Corporation Stock Analysis: Investors should monitor Masimo Corporation (MASI) due to high implied volatility in its options market, particularly the Oct 17, 2025 $70.00 Call, indicating expectations of significant price movement. Analysts have recently increased earnings estimates, suggesting a positive outlook for the company.
Quantum Computing Developments: Quantum computing is rapidly advancing, with major tech companies like Microsoft, Google, and Amazon integrating it into their operations. Stock strategist Kevin Cook has identified key stocks that may lead in this emerging field, presenting an opportunity for investors to capitalize on the next technological revolution.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MASI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MASI
Wall Street analysts forecast MASI stock price to rise
6 Analyst Rating
4 Buy
2 Hold
0 Sell
Moderate Buy
Current: 175.330
Low
162.00
Averages
188.40
High
210.00
Current: 175.330
Low
162.00
Averages
188.40
High
210.00
About MASI
Masimo Corporation is a global medical technology company that develops and produces a wide range of monitoring technologies, including measurements, sensors, patient monitors, automation and connectivity solutions. The Company’s healthcare products and patient monitoring solutions generally incorporate a monitor or circuit board, proprietary single-patient use or reusable sensors, software and/or cables. It primarily sells its healthcare products to hospitals, emergency medical service providers, home care providers, physician offices, veterinarians, long-term care facilities. Its measurement technologies include Measure-through Motion and Low Perfusion pulse oximetry, known as Masimo Signal Extraction Technology (SET) pulse oximetry, and advanced rainbow Pulse CO-Oximetry parameters such as noninvasive hemoglobin (SpHb), alongside many other modalities, including brain function monitoring, hemodynamic monitoring, regional oximetry, capnography and gas monitoring, and others.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Acquisition Investigation: Former Louisiana Attorney General Charles C. Foti and his law firm Kahn Swick & Foti are investigating the proposed sale of Masimo Corporation to Danaher Corporation for $180.00 per share, aiming to assess whether this transaction undervalues Masimo.
- Shareholder Rights Concern: The investigation focuses on whether Masimo shareholders are receiving adequate compensation, and those who believe the transaction undervalues the company can contact KSF to discuss their legal rights and express potential objections to the sale.
- Legal Consultation Access: KSF offers no-obligation legal consultations, allowing shareholders to reach out via email or phone to KSF Managing Partner Lewis S. Kahn, ensuring their rights are protected and gaining insights into the legal implications of the transaction.
- Company Background Insight: Masimo Corporation holds a significant position in the medical device sector, and if the acquisition proceeds, it could have profound implications for its future development and market competitiveness, warranting close attention from investors and market participants.
See More
- Legal Investigation Initiated: Halper Sadeh LLC is investigating VerifyMe, Inc.'s merger with Open World Ltd. for potential breaches of fiduciary duties to shareholders, aiming to protect investor rights and ensure transparency.
- Acquisition Deal Scrutiny: Masimo Corporation's sale to Danaher Corporation for $180.00 per share raises concerns about shareholder rights, with Halper Sadeh LLC potentially seeking increased consideration or other remedies.
- Shareholder Rights Protection: Valaris Limited's sale to Transocean Ltd. for 15.235 shares of Transocean stock per common share prompts Halper Sadeh LLC to encourage Valaris shareholders to understand their legal rights to ensure fair treatment in the transaction.
- Investor Advocacy Actions: Halper Sadeh LLC represents investors globally, focusing on combating securities fraud and corporate misconduct, having successfully recovered millions for defrauded investors, showcasing its expertise in safeguarding investor rights.
See More
- New Investment Disclosure: Naya Capital Management UK Ltd disclosed on February 18 that it acquired nearly 1.6 million shares of Masimo, valued at approximately $203 million, indicating strong confidence in the company.
- Asset Allocation Insight: This investment represents 15.3% of Naya Capital's 13F assets under management, positioning Masimo as one of only five reportable holdings, highlighting its significance in the firm's portfolio.
- Market Performance Comparison: Despite Masimo's stock declining 2.6% over the past year, it surged over 34% on February 17 after Danaher announced a $9.9 billion acquisition at $180 per share, showcasing a dramatic price increase from $130.15.
- Investment Risk Advisory: While Naya Capital's timing appears fortuitous, the uncertainty surrounding the acquisition poses significant downside risks for investors, suggesting a cautious approach and potential recommendation to hold off on purchasing shares.
See More
- New Position: Naya Capital Management initiated a position in Masimo (NASDAQ:MASI) by purchasing approximately 1.6 million shares valued at nearly $203 million, representing 15.3% of the fund's 13F assets under management.
- Portfolio Overview: Naya Capital's portfolio consists of only five reportable holdings totaling over $1.3 billion, with Masimo being the fifth-largest position, indicating a significant commitment to the company.
- Market Performance: Despite Masimo's shares declining by 2.6% over the past year, they surged by over 34% on February 17 following Danaher's announcement to acquire the company for $9.9 billion, raising the stock price from $130.15 to $174.69.
- Investment Risk Advisory: While Naya Capital's timing appears fortunate, analysts caution that there is considerable downside risk if the acquisition deal fails, suggesting investors should proceed with caution before buying Masimo shares.
See More
- Tech Stock Sell-off: A wave of selling in technology shares is occurring as investors express uncertainty about their future value, particularly as price-to-earnings ratios shrink dramatically, which negatively impacts overall investment sentiment.
- Danaher-Masimo Acquisition Risks: Danaher is acquiring Masimo at nearly 25 times next year's earnings, despite the latter's inability to justify its multiple over the years, raising concerns that could adversely affect Danaher's stock performance.
- CrowdStrike-Microsoft Partnership: CrowdStrike's Falcon platform is now available on the Microsoft Marketplace, which could significantly boost revenue; however, its current P/E ratio of 85 has led to a tepid market reaction, reflecting investor anxiety over high valuations.
- ServiceNow Management Confidence Issues: Despite ServiceNow's announcement of a $5 billion stock buyback and intentions from executives to buy shares, the stock price still fell, indicating market skepticism about its growth prospects amid intensifying AI competition.
See More
- Transaction Background: The deal follows a proxy contest led by activist hedge fund Politan Capital Management, resulting in the removal of Masimo founder Joe Kiani as board chair, who subsequently stepped down as CEO but retains about a 5% stake, indicating significant governance changes.
- Valuation Metrics: The transaction is valued at approximately 18x estimated 2027 EBITDA, or 15x including expected annual synergies, reflecting Danaher's confidence in Masimo's future profitability and potential growth in the diagnostics sector.
- Financial Expectations: Danaher anticipates Masimo will generate over $530 million in EBITDA by 2027, with more than $125 million in annual cost synergies and over $50 million in annual revenue synergies expected by the fifth year post-acquisition, showcasing a strong financial outlook.
- Market Reaction: Danaher’s stock rose 0.55% to $207.50 in the latest trading session, indicating a positive market response to the acquisition, with analysts suggesting that the deal enhances Danaher’s portfolio of high-quality assets.
See More








